Type 1 diabetes may result from a breakdown in peripheral tolerance that is partially controlled by the expression of peripheral tissue antigens (PTAs) in lymph nodes. Here we show that the transcriptional regulator Deaf1 controls the expression of genes encoding PTAs in the pancreatic lymph nodes (PLNs). The expression of canonical Deaf1 was lower, whereas that of an alternatively spliced variant was higher, during the onset of destructive insulitis in the PLNs of nonobese diabetic (NOD) mice. We identified an equivalent variant Deaf1 isoform in the PLNs of patients with type 1 diabetes. Both the NOD mouse and human Deaf1 variant isoforms suppressed PTA expression by inhibiting the transcriptional activity of canonical Deaf1. Lower PTA expression resulting from the alternative splicing of DEAF1 may contribute to the pathogenesis of type 1 diabetes.
Type 1 diabetes may result from a breakdown in peripheral tolerance that is partially controlled by the expression of peripheral tissue antigens (PTAs) in lymph nodes. Here we show that the transcriptional regulator Deaf1 controls the expression of genes encoding PTAs in the pancreatic lymph nodes (PLNs). The expression of canonical Deaf1 was lower, whereas that of an alternatively spliced variant was higher, during the onset of destructive insulitis in the PLNs of nonobese diabetic (NOD) mice. We identified an equivalent variant Deaf1 isoform in the PLNs of patients with type 1 diabetes. Both the NOD mouse and human Deaf1 variant isoforms suppressed PTA expression by inhibiting the transcriptional activity of canonical Deaf1. Lower PTA expression resulting from the alternative splicing of DEAF1 may contribute to the pathogenesis of type 1 diabetes.
Type 1 diabetes results from the autoimmune destruction of pancreatic b-cells by self-reactive T cells in genetically susceptible people because of a breakdown in central and/or peripheral tolerance. Central tolerance is enforced by medullary thymic epithelial cells that ectopically express a range of peripheral tissue antigens (PTAs) under the transcriptional control of the autoimmune regulator Aire 1 . Most maturing thymocytes that express T cell antigen receptors (TCRs) specific for these PTAs are deleted, but some self-reactive T cells escape to the periphery, where additional tolerance mechanisms are in place to protect tissues from autoimmune attack. In addition to being mediated by regulatory T cells, peripheral tolerance can be mediated by lymph node stromal cells and extrathymic Aire-expressing cells, which present PTA peptides on major histocompatibility complex molecules and engage autoreactive PTAspecific T cells, which ultimately leads to their clonal deletion [2] [3] [4] . The mechanisms that control PTA expression in secondary lymphoid tissues are not completely understood.
Comparison of gene expression in tissues from nonobese diabetic (NOD) mice, a model of type 1 diabetes, with that of NOD.B10 mice, a congenic strain that does not develop disease, has shown that expression of the gene encoding the transcriptional regulator Deaf1 changes in parallel with the expression of genes encoding several islet-specific tissue antigens, including insulin 1, insulin 2, glucagon, pancreatitis-associated protein, pancreatic polypeptide and regenerating islet-derived IIIa and IIIg in the pancreatic lymph nodes (PLNs) 5 . The expression of Deaf1 and genes encoding these islet-specific antigens is substantially downregulated in the PLNs of NOD mice at the age of 12 weeks 5 , a time coincident with the onset of destructive insulitis.
In addition, Deaf1 regulates the expression of genes encoding certain PTAs in lymph node stromal elements. Here we show that Deaf1 can be processed into at least two isoforms in the PLNs of NOD mice: a canonical Deaf1 isoform that is able to translocate to the nucleus and is required for PTA expression, and a splice variant that is expressed in the cytoplasm and inhibits the transcriptional activity of canonical Deaf1. Notably, expression of a similar alternatively spliced Deaf1 isoform was significantly higher in the PLNs of patients with type 1 diabetes.
RESULTS

Deaf1 isoforms and PTA expression in NOD PLNs
Microarray analysis demonstrated that the expression of various pancreatic genes and Deaf1 changed in parallel over time in the PLNs of NOD mice 5 (Fig. 1a,b) . Two probes (probe 1 and 2) that bind to Deaf1 were present on the microarray, but only probe 1 showed an expression profile similar to that of the genes encoding pancreatic PTAs (Fig. 1a) . Probe 1 hybridized to a Deaf1 region spanning exons 6 and 7, whereas probe 2 hybridized to a region in exon 11 (Fig. 1c) . The discordant expression profiles demonstrated by the two probes suggested that more than one Deaf1 isoform might exist in the PLNs and that the relative expression of the two isoforms might change with age.
PCR cloning and sequence analysis of Deaf1 mRNA in PLN tissue identified the canonical mRNA (DF1; GenBank accession code FJ377319) as well as an alternatively spliced transcript containing an insertion between exons 6 and 7 (DF1-VAR1; GenBank accession code FJ377318; Fig. 1c ) that resulted in disruption of the binding site of probe 1. Thus, changes in the expression of these two Deaf1 isoforms could explain the discordant patterns of expression demonstrated by the two probes (Fig. 1b) .
Our microarray experiments (Fig. 1a) used a pool of PLN mRNA from 1.5-and 20-week-old NOD.B10 mice as controls 5 . Next we quantified the expression of DF1 and DF1-VAR1 in NOD and NOD.B10 mice at various ages by quantitative PCR (Fig. 2 and Supplementary Figs. 1 and 2). The Taqman probe for DF1 spans exons 6 and 7, at the intronic insertion site, and the DF1-VAR1 primer and probes were designed to hybridize in the intronic insertion ( Supplementary Fig. 1 ).
The expression of DF1 and DF1-VAR1 did not differ in the PLNs of NOD mice versus NOD.B10 mice at 4 weeks of age (Fig. 2a,b) . However, at 12 weeks, DF1 expression was downregulated and DF1-VAR1 expression was upregulated specifically in NOD PLNs. In contrast, expression of GAPDH mRNA (encoding glyceraldehyde phosphate dehydrogenase) did not differ in PLNs from 12-week-old NOD mice versus NOD.B10 mice (Fig. 2c) . The changes in DF1 and DF1-VAR1 expression seem specific to the PLNs, as we found no significant difference in spleen tissues of 12-week-old NOD versus NOD.B10 mice (Fig. 2d) .
Characterization of Deaf1 isoforms
Canonical DF1 contains an amino-terminal alanine-rich region, the SAND (Sp100, Aire-1, NucP41/75 and Deaf1) and ZF-MYND (zinc finger, myeloid, Nervy and Deaf1) domains, a helix-loop-helix domain, and a nuclear-localization sequence (NLS) and nuclearexport sequence. The DF1-VAR1 transcript contains part of intron 7, which introduces a premature stop codon that results in a truncated protein lacking part of the NLS as well as the helix-loop-helix, nuclearexport sequence and ZF-MYND domain. DF1-VAR1 also has a 42-base pair (bp) deletion in the alanine-rich region (Fig. 1c) .
DF1 is about 70 kilodaltons (kDa) in size and localized in the nucleus of human embryonic kidney (HEK293) cells (Fig. 3a,b) . DF1-VAR1 is about 50 kDa in size and was distributed throughout the cytoplasm (Fig. 3a,b) . Notably, transient coexpression of DF1 with DF1-VAR1 resulted in nuclear localization of some DF1-VAR1, as shown by immunofluorescence (Fig. 3b) . That finding was confirmed by immunoblot analysis (Fig. 3c) . Coimmunoprecipitation studies with Flag-tagged DF1 and V5 epitope-tagged DF1-VAR1 demonstrated that DF1 and DF1-VAR1 were able to interact (Fig. 3d) . These data suggest that the DF1 and DF1-VAR1 form heterodimeric complexes that can shuttle DF1-VAR1 into the nucleus using the NLS domain of DF1.
We examined the transcriptional activity of DF1 and DF1-VAR1 with a 26-bp DEAF1 response element-luciferase reporter plasmid 6 . When transiently transfected into HEK293 cells, DF1 fused with enhanced green fluorescent protein (DF1-eGFP) induced greater luciferase reporter activity than did DF1-VAR1-eGFP (Fig. 3e) . The lower transcriptional activity of DF1-VAR1 may have been due to its cytoplasmic localization and diminished ability to translocate to the nucleus (Fig. 3b) . Cotransfection of DF1-VAR1 and DF1 resulted in much less transcriptional activity than did transfection of equivalent amounts of DF1 alone (Fig. 3f) .
Analysis of Deaf1-deficient BALB/c mice To examine the genes regulated by Deaf1 in PLNs, we did wholegenome microarray analysis of Deaf1-deficient BALB/c PLN tissues. Approximately 300 genes were upregulated and 300 were downregulated by B2.5-fold in Deaf1-deficient mice relative to that in BALB/c controls ( Fig. 4a and Supplementary Tables 1 and 2) . Notably, among the 30 genes whose expression was most downregulated in Deaf1-deficient PLNs, almost three quarters were considered to encode potential PTAs with expression limited to five tissues or less; in contrast, less than one quarter of the 'middle' 30 genes, whose expression was unchanged in Deaf1-deficient mice, were expressed in five tissues or less (Supplementary Table 3 ). There was little overlap between the genes regulated by Deaf1 in the PLNs and those regulated by Aire in extrathymic Aire-expressing cells ( Supplementary Fig. 3 ). We found two Aire-regulated genes, Ambp (encoding the a1-microglobulin AMBP) and Fgb (encoding the fibrinogen b-chain FGB), among the 20 genes most downregulated in the PLNs of Deaf1-deficient mice. Reg3g and Ppy, which encode pancreas-specific antigens RegIIIg and pancreatic polypeptide (PPY), respectively, are also regulated by Aire in the thymus 1 . To accurately measure the expression of Reg3g, Ppy, Ambp and Fgb in the PLNs of Deaf1-deficient and control mice, we used SYBR Green quantitative PCR assays. We confirmed the specificity and amplification efficiency of each assay by RT-PCR, melting-curve analysis and standard curves ( Supplementary  Fig. 4 ). The expression of RegIIIg, PPY, AMBP and FGB mRNA was significantly lower in the PLNs of Deaf1-deficient mice than in those of wild-type controls (Fig. 4b) . Notably, the expression of those same genes was upregulated in the thymus of Deaf1-deficient mice, possibly because of higher Aire mRNA expression in the thymus of Deaf1-deficient mice (Fig. 4c) ; Aire mRNA quantities were not different in the PLNs of Deaf1-deficient versus control mice (Fig. 4b) . Unexpectedly, the amount of insulin 2 mRNA in the PLNs in the PLNs of Deaf1-deficient and BALB/c control mice was 0.06-3% that in the PLNs of NOD and NOD.B10 mice ( Supplementary Fig. 5 ) and thus was not detected by our microarray analysis.
To determine if 30-week-old Deaf1-deficient mice showed signs of autoimmunity, we looked for lymphocyte infiltration in various tissues and for the presence of autoantibodies. We did not detect lymphocyte infiltration in the pancreas, salivary glands, thyroid, gut or kidney (data not shown). The serum of Deaf1-deficient mice reacted with certain proteins (B15-25 kDa) in whole-eye lysates (Fig. 4d) but not with lysates of any other tissues examined (brain, salivary gland, heart, lung, liver, kidney, pancreas, spleen and gut). Autoantibodies in Deaf1-deficient serum reacted with the outer segment layer of the retina, similar to autoantibodies in Aire-deficient mice 1 (Fig. 4e) .
Influence of Deaf1 isoforms on PTA expression Next we used small interfering RNA (siRNA) to silence the expression of Deaf1 in the NIH3T3 fibroblast cell line, which expresses endogenous Deaf1, Ambp and Fgb, to examine Deaf1-mediated regulation of the PTAs encoded by these genes. Deaf1-specific siRNA significantly inhibited the expression of DF1-Flag, as well as the expression of endogenous Deaf1, in NIH3T3 cells (Fig. 5a,b) , which demonstrated the specificity of this siRNA. Deaf1-specific siRNA also resulted in significant suppression of the expression of AMBP and FGB mRNA relative to their expression after transfection of 'nonsense' siRNA (Fig. 5c) . However, overexpression of DF1 in NIH3T3 cells did not upregulate Fgb expression and resulted in only slightly higher Ambp expression ( Supplementary Fig. 6 ). These data indicate that whereas lower DF1 expression result in lower expression of genes encoding PTAs, higher DF1 expression alone may not be sufficient to enhance the expression of such genes. and 6a), whereas higher DF1 expression detected in PLNs from 20-week-old NOD mice did not correlate with higher expression of genes encoding PTAs (Fig. 6a) .
Next we sought to identify the cell type(s) in which changes in DF1-VAR1 expression occurred in PLNs from 12-week-old NOD mice. We found that DF1-VAR1 expression was approximately sevenfold and tenfold higher in lymph node stromal elements from PLNs from 12-week-old NOD mice than in T cells and B cells, respectively, from the same mice (Fig. 6b) . Silencing of Deaf1 in CD45 -immortalized lymph node cells from pooled lymph nodes of BALB/c mice resulted in lower expression of AMBP and FGB mRNA (Fig. 6c,d) . Similarly, overexpression of DF1-VAR1 in these cells resulted in lower expression of AMBP and FGB mRNA (Fig. 6e) . Although overexpression of DF1-VAR1 did not alter the expression of DF1 (Fig. 6e) , we propose that it interfered with the transcriptional activity of DF1 by interacting with and retaining it in the cytoplasm. In support of that hypothesis, immunoblot analysis of nuclear and cytoplasmic extracts from HEK293 cells transfected with DF1-Flag and/or DF1-VAR1-eGFP showed that cells transfected with both DF1-VAR1 and DF1 had more cytoplasmic DF1 and less nuclear DF1 than did cells transfected with DF1 alone (Fig. 6f) . These data suggest that DF1-VAR1 can diminish the expression of genes encoding PTAs by interacting with and retaining DF1 in the cytoplasm.
Alternatively spliced human Deaf1 variant
To examine if an alternatively spliced variant of DEAF1 is expressed in human PLNs, we did RT-PCR with human PLN cDNA as a template and primers that spanned the start and stop codons of human DEAF1 (Supplementary Table 4) . These primers amplified the canonical human DEAF1 transcript (Hu-DF1; GenBank accession code BC053322) as well as an alternatively spliced variant that lacks exons 5 and 7 and the first nucleotide of exon 6 (Hu-DF1-VAR; GenBank accession code FJ985253). This variant transcript also contains an intronic 42-bp insertion between exons 10 and 11 that is expressed in-frame from the start to stop codons and contains intact SAND and MYND domains but lacks the NLS domain encoded by exon 7 (Fig. 7a) .
Characterization of the Hu-DF1-VAR isoform showed many similarities with the mouse DF1-VAR1 isoform. Hu-DF1-VAR was expressed mainly in the cytoplasm (Fig. 7b) and did not mediate transcriptional activation of the 26-bp DEAF1 response element (Fig. 7c) . This variant interacted with canonical Hu-DF1 and altered its distribution in the cell. When expressed alone, Hu-DF1 localized almost exclusively in the nucleus (Fig. 7b,d ), but when expressed together with Hu-DF1-VAR, its nuclear expression decreased to 32% of DF1 alone and its cytoplasmic expression increased by 270%. In contrast, coexpression of the two isoforms enhanced the nuclear localization of Hu-DF1-VAR (Fig. 7e) .
To determine if the alternatively spliced isoform of DEAF1 is upregulated in the PLNs in patients with type 1 diabetes, we did quantitative PCR with primers that spanned the two deletion sites of the Hu-DF1-VAR transcript ( Table 1 and Supplementary Fig. 7 ). Expression of Hu-DF1-VAR was about 20-fold higher in the PLNs of patients with type 1 diabetes than in those of healthy controls (Fig. 7f) . This finding strongly correlated with the lack of expression of the gene encoding insulin (INS) in the PLNs of all patients with type 1 diabetes studied ( Table 1) . We detected INS expression in four of five of the control PLNs and in the spleen for all samples. The spleen samples had either no expression of Hu-DF1-VAR or expression of Hu-DF1-VAR similar to that of control PLNs (data not shown). Together these data suggest that during the progression of human type 1 diabetes, DEAF1 is alternatively spliced to produce a nonfunctional variant similar to mouse DF1-VAR1. The Hu-DF1-VAR isoform interacts with and inhibits the transcriptional activity of canonical Hu-DF1 by retaining it in the cytoplasm.
DISCUSSION
Type 1 diabetes develops from a breakdown in central or peripheral tolerance that is partially controlled by PTA expression in the thymus and lymph nodes, respectively. Here we have demonstrated that Deaf1 is involved in regulating the expression of genes encoding PTAs in peripheral lymphoid tissues. We found that the transcriptional activity of Deaf1 was inhibited by alternatively spliced variants of Deaf1 and that the expression of these splice variants was significantly higher in the PLNs of patients with type 1 diabetes and 12-week-old NOD mice than in controls. These findings suggest that alternative splicing of DEAF1 or Deaf1 could serve a key function in the pathogenesis of type 1 diabetes and NOD disease. The age of 12 weeks is pivotal in the progression of NOD disease, as infiltrative insulitis and b-cell destruction begins at this age 7 . Peripheral tolerance to certain PTAs is facilitated in the lymph nodes through the ectopic expression of genes encoding PTAs in stromal cells [2] [3] [4] , and defects in peripheral tolerance may induce infiltrative insulitis. The expression of genes encoding various pancreatic PTAs is diminished in the PLNs of NOD mice at 12 weeks of age 5 . This coincides with downregulation of DF1 expression and upregulation of DF1-VAR1 expression. As DF1-VAR1 inhibits the expression of genes encoding PTAs and interferes with the transcriptional activity of DF1, a change in Deaf1 isoform expression may result in lower PTA expression in PLNs from 12-week-old NOD mice and lower tolerance to these antigens.
Because of the obvious practical difficulties in obtaining human PLN tissues from prediabetic patients as well as those at disease onset, we could not assess the expression of Hu-DF1 and Hu-DF1-VAR throughout all stages of the natural history of type 1 diabetes. In the one prediabetic PLN sample we obtained, Hu-DF1-VAR expression was higher than that in the PLNs of all the healthy control samples examined. Notably, the higher expression of Hu-DF1-VAR and absence of INS in the PLNs seemed to be maintained well after the onset of type 1 diabetes.
Higher expression of the Deaf1 variant leads to more formation of heterodimeric complexes that retain the canonical isoform in the cytoplasm, thus dimnishing the transcriptional activity of the canonical isoform. Both DF1-VAR1 and Hu-DF1-VAR lack the NLS domain that is required for nuclear localization and activation of gene transcription 8 , and both induced much less transcriptional activity of the 26-bp DEAF1 response element than did DF1 or Hu-DF1. The canonical isoform of Deaf1 is structurally similar to Aire, which also contains a SAND domain and can induce the expression of genes encoding PTAs by interacting with modified and unmodified histone H3 through its pleckstin homology domain-zinc finger domain 9, 10 . We suggest that Deaf1, rather than Aire, is involved in controlling PTA expression in PLNs. Deaf1 may regulate PTA expression in a way analogous to Aire, as both proteins contain similar functional domains: Deaf1 contains a carboxy-terminal ZF-MYND domain that is structurally similar to the pleckstin homology domainzinc finger domain, as well as a SAND domain that functions as a DNA-binding domain for chromatin-dependent transcription and a site for protein-protein interaction 11, 12 . However, the effect of Deaf1 function may be cell dependent. For example, Deaf1 represses and enhances promoter activity of the gene encoding the serotonin receptor 5-HT1A in presynaptic and postsynaptic neurons, respectively 13 . In addition, some genes were upregulated whereas others were downregulated in Deaf1-deficient mice, which suggests that Deaf1 may interact with cell-specific regulatory factors to either stimulate or suppress gene transcription. The requirement for additional factors may explain why overexpression of DF1 did not result in significantly higher expression of genes encoding PTAs in NIH3T3 cells and why changes in such expression in PLN tissue did not necessarily correlate with higher DF1 expression.
BALB/c mice in which Deaf1 was knocked out did not manifest an obvious autoimmune phenotype. However, like the serum of Airedeficient mice, the serum of Deaf1-deficient mice contained autoantibodies that were immunoreactive to proteins in the retina of the eye 1 . Notably, our microarray data showed that the gene most downregulated in the PLNs of Deaf1-deficient mice was Dct, which encodes a protein (dopachrome tautomerase) that is expressed exclusively in the retina. In addition, three other genes among the 30 genes most downregulated in the PLNs of Deaf1-deficient mice (1500016O10Rik, Si and Sgne1) are expressed in the retina. Control of the expression of retinal antigens by Deaf1 may be of particular importance, as less antigen presentation in eye-draining lymph nodes prevents autoreactive T cell deletion and contributes to the development of retinal autoimmunity 14 .
Variations in the thymic expression of genes encoding PTAs can influence susceptibility to autoimmune disease 15, 16 . The expression of genes encoding certain PTAs was lower in the PLNs of Deaf1-deficient mice, whereas, unexpectedly, the expression the same genes and of Aire was higher in the thymus of Deaf1-deficient mice. This suggests the possibility that enhanced central tolerance mechanisms, mediated by higher Aire-regulated expression of PTAs in the thymus, may result in the lack of overt autoimmunity in Deaf1-deficient mice. Straindependent variations in the thymic expression of genes encoding certain PTAs, such as the uveitogenic retinal antigen IRBP, have been reported 17 . Published studies have also shown that the severity of the autoimmune phenotype of Aire-knockout mice depends on the genetic background. Aire-deficient mice develop severe exocrine pancreatitis on the NOD background but not on the C57BL/6 or BALB/c background 18 , whereas autoimmune gastritis and autoantibodies to Mucin-6 develop in Aire-deficient mice on the NOD and BALB/c backgrounds but not on the C57BL/6 background 19 . The phenotype of the Deaf1-deficient mice is also strain specific. On the C57BL/6 background, Deaf1-deficient mice suffer from various developmental defects not reported for BALB/c Deaf1-deficient mice 20 .
Ambp, Fgb, Ppy and Reg3g were downregulated in the PLNs of Deaf1-deficient mice, and we selected these genes for further study on the basis of their regulation by Aire in the thymus 1 and lower expression in the PLNs of 12-week-old NOD mice. Medullary thymic epithelial cells and lymph node stromal cells have low expression of PTAs. For example, PTA expression in lymph nodes has been assessed with the iFABP-tOVA transgenic mouse model, in which ovalbumin (OVA) represents a self antigen expressed under the control of the promoter of the gene encoding fatty acid-binding protein (FABP) 2 . These studies report that OVA mRNA expression is detected in lymph nodes by RT-PCR, but OVA protein is not detected by immunoblot analysis. Similarly, PTA expression is low in the thymus, as only a small subset of medullary thymic epithelial cells ectopically express Aire and PTAs 1, 21, 22 .
In humans, INS was not detected in the PLNs of patients with type 1 diabetes, but it was expressed in the PLNs of healthy people and in the spleen for both control and type 1 diabetes samples. The lack of INS expression correlated well with the high expression of Hu-DF1-VAR in the PLNs of patients with type 1 diabetes. In PLNs from 12-week-old NOD mice, Ins2 gene expression was also lower, but we did not detect a difference in insulin 2 mRNA expression in the PLNs of Deaf1-deficient mice versus BALB/c control mice. This may have been due to the fact that the amount of insulin 2 mRNA expressed in the PLNs of Deaf1-deficient and BALB/c control mice was 0.06-3% the amount expressed in those of NOD and NOD.B10 mice.
Members of the Reg family have been described as autoantigens in type 1 diabetes, and the inflammation-induced upregulation of Reg expression in islets is suggested to contribute to the premature onset of diabetes 23 . We have shown that Reg3g expression was downregulated in the PLNs of Deaf1-deficient mice and 12-week-old NOD mice, but we were unable to determine if Deaf1 directly regulated Reg3g expression, as the NIH3T3 and LN CD45 -cell lines that we used for the siRNA experiments did not have measurable expression of Reg3g. Loss of endogenous expression of genes encoding PTAs has been shown to occur in cultured medullary thymic epithelial cells 24 and lymph node stromal cell lines (unpublished data). Thus, experiments involving monoclonal antibodies to DF1-VAR1 and/or in situ hybridization studies of primary lymph node stromal elements derived from the PLNs of NOD and NOD.B10 mice may be needed to identify the actual stromal cell that expresses the variant Deaf1 isoforms and to determine the direct function of Deaf1 in the expression of genes encoding PTAs. Although the expression of Ambp, Fgb, Ppy and Reg3g is regulated by Aire in the thymus, the expression of these genes in the PLNs is more probably regulated by Deaf1. Aire expression was not altered in the PLNs of Deaf1-deficient mice or NOD mice, and most of the PTAs regulated by Aire in extrathymic Aire-expressing cells seem to be distinct from those regulated by Deaf1 in the PLNs.
Our study suggest that Deaf1 promotes the ectopic expression of genes encoding PTAs in the PLNs, and it is known that PTA expression in lymph node stromal cells can mediate peripheral tolerance 2 . Thus, 'fine tuning' of peripheral tolerance, at least in the PLNs, may occur through alternative splicing of Deaf1. Alternative splicing is a mechanism that is often used to control immune responses. However, variations in splicing can impair immune function and contribute to various autoimmune diseases 25 . It is unclear how splicing of Deaf1 is controlled, but inflammation of NOD PLNs may be involved, as various inflammatory cytokines have been shown to induce alternative splicing [26] [27] [28] [29] [30] . Differences in Deaf1 splicing in NOD versus NOD.B10 mice may also be due to other genes in the insulin-dependent diabetessusceptibility region, a major histocompatibility complex congenic interval that distinguishes the two strains. Allelic variation of such genes or differences in their regulatory regions may influence their expression or function, which may be associated with splicing events.
We propose that during the progression of type 1 diabetes and NOD disease, alternative splicing of Deaf1 occurs in the PLNs. The alternatively spliced Deaf1 variant interacts with and retains the canonical isoform in the cytoplasm and inhibits the expression of genes encoding PTAs. Lower expression of pancreatic antigens in the PLNs may impair peripheral tolerance and lead to the survival of autoreactive T cells specific for these antigens. Thus, we suggest that differences in the expression of Deaf1 isoforms in the PLNs of humans with type 1 diabetes and NOD mice may contribute to the development of this disease.
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